1. Home
  2. CXT vs CELC Comparison

CXT vs CELC Comparison

Compare CXT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crane NXT Co.

CXT

Crane NXT Co.

HOLD

Current Price

$41.51

Market Cap

3.1B

Sector

Industrials

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$113.10

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXT
CELC
Founded
1855
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
CXT
CELC
Price
$41.51
$113.10
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$76.75
$106.63
AVG Volume (30 Days)
688.2K
526.7K
Earning Date
05-06-2026
03-25-2026
Dividend Yield
1.74%
N/A
EPS Growth
N/A
N/A
EPS
2.50
N/A
Revenue
$3,374,900,000.00
N/A
Revenue This Year
$5.75
N/A
Revenue Next Year
$4.22
N/A
P/E Ratio
$16.57
N/A
Revenue Growth
6.13
N/A
52 Week Low
$41.43
$7.58
52 Week High
$69.00
$120.32

Technical Indicators

Market Signals
Indicator
CXT
CELC
Relative Strength Index (RSI) 21.93 53.84
Support Level N/A $97.75
Resistance Level $61.93 $117.27
Average True Range (ATR) 1.50 5.38
MACD -0.52 -0.07
Stochastic Oscillator 10.32 58.88

Price Performance

Historical Comparison
CXT
CELC

About CXT Crane NXT Co.

Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: